본문 바로가기
KERD
논문KCI 등재

Therapeutic New Era for Atopic Dermatitis: Part 1. Biologics

최유성|안지영|Simpson Eric Lawrence
대한피부과학회 (Korean Dermalogical Association)|2021.02|Annals of Dermatology|제33권 제1호|pp. 1-10|DOI 10.5021/ad.2021.33.1.1

6

조회

0

다운로드

2

인용

0

참고문헌

키워드

Atopic dermatitisTherapeuticsBiologicsNew era
주제분류피부과학

초록

Atopic dermatitis (AD) is a chronic, inflammatory cutaneous disease driven by immune dysregulation and skin barrier dysfunction. We are currently experiencing a new era of understanding of the pathogenesis of AD and, as a consequence, a new era of innovation in therapeutics, including small molecules and biologic therapy. Recently, advances in translational research have challenged the traditional AD pathogenesis paradigm of AD being solely a Th2-dominant disease. Other immune pathways seem to play a role in the complex AD pathophysiology, although the clinical relevance of these additional immune pathway abnormalities is unclear. Type 1, type 22, and type 17 pathway activation (with related cytokines/chemokines) have been demonstrated in the skin and blood of AD patients. Type 2 (interleukin [IL]-4, IL-13), IL-31, and type 22 (IL-22) pathway cytokines are increased in AD acute lesions. IL-22 induces both an epidermal hyperplasia at the onset of acute AD and a marked increase in the terminal differentiation S100 genes. This understanding of pathogenesis corresponds to a historic increase in therapeutic development in AD. The extreme clinical heterogeneity and the chronic progression of AD establish the need for newer, safer, and more effective treatments, control the disease, and improve the quality of life of affected patients.

Abstract

Atopic dermatitis (AD) is a chronic, inflammatory cutaneous disease driven by immune dysregulation and skin barrier dysfunction. We are currently experiencing a new era of understanding of the pathogenesis of AD and, as a consequence, a new era of innovation in therapeutics, including small molecules and biologic therapy. Recently, advances in translational research have challenged the traditional AD pathogenesis paradigm of AD being solely a Th2-dominant disease. Other immune pathways seem to play a role in the complex AD pathophysiology, although the clinical relevance of these additional immune pathway abnormalities is unclear. Type 1, type 22, and type 17 pathway activation (with related cytokines/chemokines) have been demonstrated in the skin and blood of AD patients. Type 2 (interleukin [IL]-4, IL-13), IL-31, and type 22 (IL-22) pathway cytokines are increased in AD acute lesions. IL-22 induces both an epidermal hyperplasia at the onset of acute AD and a marked increase in the terminal differentiation S100 genes. This understanding of pathogenesis corresponds to a historic increase in therapeutic development in AD. The extreme clinical heterogeneity and the chronic progression of AD establish the need for newer, safer, and more effective treatments, control the disease, and improve the quality of life of affected patients.

참고문헌 (59)

  1. Simpson EL, "Two phase 3 trials of dupilumab versus placebo in atopic dermatitis", N Engl J Med, 375, pp.2335~2348 (2016)
  2. Fölster-Holst R, "Management of atopic dermatitis : are there differences between children and adults", J Eur Acad Dermatol Venereol, 28(Suppl 3), pp.5~8 (2014)
  3. Silverberg JI, "Adult-onset atopic dermatitis", J Allergy Clin Immunol Pract, 7, pp.28~33 (2019)
  4. Hanifin JM, "Adult-onset atopic dermatitis : fact or fancy", Dermatol Clin, 35, pp.299~302 (2017)
  5. Valdes-Rodriguez R, "Chronic pruritus in the elderly: pathophysiology, diagnosis and management", Drugs Aging, 32, pp.201~215 (2015)
  6. Brunner PM, "The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies", J Allergy Clin Immunol, 139(4S), pp.S65~S76 (2017)
  7. Moyle M, "Understanding the immune landscape in atopic dermatitis : the era of biologics and emerging therapeutic approaches", Exp Dermatol, 28, pp.756~768 (2019)
  8. Gittler JK, "Progressive activation of T(H)2", T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis, 2012, pp.130, 1344~1354
  9. Sehra S, "IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation", J Immunol, 184, pp.3186~3190 (2010)
  10. Boniface K, "IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes", J Immunol, 174, pp.3695~3702 (2005)
  11. Howell MD, "Cytokine modulation of atopic dermatitis filaggrin skin expression", J Allergy Clin Immunol, 120, pp.150~155 (2007)
  12. Kim BE, "Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6", Clin Immunol, 126, pp.332~337 (2008)
  13. Tsoi LC, "Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis", J Invest Dermatol, 139, pp.1480~1489 (2019)
  14. Blauvelt A, "Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS):a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial", Lancet, 389, pp.2287~2303 (2017)
  15. de Bruin-Weller M, "Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebocontrolled, randomized phase III clinical trial (LIBERTY AD CAFÉ)", Br J Dermatol, 178, pp.1083~1101 (2018)
  16. Simpson EL, "Two phase 3 trials of dupilumab versus placebo in atopic dermatitis", N Engl J Med, 376, pp.1090~1091 (2017)
  17. Blauvelt A, "Dupilumab does not affect correlates of vaccine-induced immunity: a randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis", J Am Acad Dermatol, 80, pp.158~167 (2019)
  18. Eichenfield LF, "Infections in dupilumab clinical trials in atopic dermatitis : a comprehensive pooled analysis", Am J Clin Dermatol, 20, pp.443~456 (2019)
  19. Callewaert C, "IL-4Rα blockade by dupilumab decreases staphylococcus aureus colonization and increases microbial diversity in atopic dermatitis", J Invest Dermatol, 140, pp.191~202 (2020)
  20. Akinlade B, "Conjunctivitis in dupilumab clinical trials", Br J Dermatol, 181, pp.459~473 (2019)
  21. Wollenberg A, "Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment", J Allergy Clin Immunol Pract, 6, pp.1778~1780 (2018)
  22. Thyssen JP, "Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy-international eczema council survey and opinion", J Eur Acad Dermatol Venereol, 33, pp.1224~1231 (2019)
  23. Thyssen JP, "Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis", J Am Acad Dermatol, 77, pp.280~286 (2017)
  24. Voorberg AN, "Recurrence of conjunctival goblet cells after discontinuation of dupilumab in a patient with dupilumab-related conjunctivitis", J Eur Acad Dermatol Venereol, 34, pp.e64~e66 (2020)
  25. Aszodi N, "Management of dupilumab-associated conjunctivitis in atopic dermatitis", J Dtsch Dermatol Ges, 17, pp.488~491 (2019)
  26. Faiz S, "Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort", J Am Acad Dermatol, 81, pp.143~151 (2019)
  27. Uchida H, "Real-world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients : a single-centre retrospective study", Br J Dermatol, 181, pp.1083~1085 (2019)
  28. Fargnoli MC, "Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis", J Dermatolog Treat (2019)[DOI]
  29. Ariëns LFM, "Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis paients : first clinical and biomarker results from the BioDay registry", Allergy, 75, pp.116~126 (2020)
  30. Jang DH, "Treatment of moderate to severe atopic dermatitis with Dupilumab: real world practice in Korea", Proceedings of the Korean Dermatological Association the 71st Autumn meeting (2019)
  31. Wang C, "Real-world experience of dupilumab treatment for atopic dermatitis in adults : a retrospective analysis of patients’ records", Int J Dermatol, 59, pp.253~256 (2020)
  32. Ruiz-Villaverde R, "Fifty-two week follow-up safety and effectiveness results of dupilumab treatment of moderate-to-severe atopic dermatitis from a retrospective, multicentric series", Dermatol Ther, 32, pp.e12931~ (2019)
  33. Yoseph D, "First reported case of facial rash after Dupilumab therapy", Pract Dermatol, pp.25~26 (2018)
  34. Albader SS, "Dupilumab side effect in a patient with atopic dermatitis : a case report study", Biologics, 13, pp.79~82 (2019)
  35. de Wijs LEM, "Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab : a case series", Br J Dermatol, 183, pp.745~749 (2020)
  36. Cork MJ, "Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis : results from a phase IIa open-label trial and subsequent phase III open-label extension", Br J Dermatol, 182, pp.85~96 (2020)
  37. Werfel T, "Cellular and molecular immunologic mechanisms in patients with atopic dermatitis", J Allergy Clin Immunol, 138, pp.336~349 (2016)
  38. Karo-Atar D, "Therapeutic targeting of the interleukin-4", interleukin-13 signaling pathway : in allergy and beyond, 2018, pp.32, 201~220
  39. Wollenberg A, "Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb", J Allergy Clin Immunol, 143, pp.135~141 (2019)
  40. Simpson EL, "Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-tosevere atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE)", J Am Acad Dermatol, 78, pp.863~871 (2018)
  41. Guttman-Yassky E, "Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial", JAMA Dermatol, 156, pp.411~420 (2020)
  42. Chen YL, "Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis", Sci Transl Med, 11 (2019)
  43. Huth S, "Effects of a ceramide-containing water-in-oil ointment on skin barrier function and allergen penetration in an IL-31 treated 3D model of the disrupted skin barrier", Exp Dermatol, 27, pp.1009~1014 (2018)
  44. Silverberg JI, "Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus", J Allergy Clin Immunol, 145, pp.173~182 (2020)
  45. Kabashima K, "Nemolizumab in patients with moderate-tosevere atopic dermatitis: randomized, phase II, long-term extension study", J Allergy Clin Immunol, 142, pp.1121~1130 (2018)
  46. "A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis" (2012)[URL]
  47. Mikhak Z, "First-in-human study of KPL-716, Anti-Oncostatin M receptor beta monoclonal antibody, in healthy volunteers and subjects with atopic dermatitis", Proceedings of the 27th Congress of the European Academy of Dermatology and Venereology (2018)
  48. Soumelis V, "Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP", Nat Immunol, 3, pp.673~680 (2002)
  49. Matera MG, "TSLP inhibitors for asthma : current status and future prospects", Drugs, 80, pp.449~458 (2020)
  50. Simpson EL, "Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial", J Am Acad Dermatol, 80, pp.1013~1021 (2019)
  51. Guttman-Yassky E, "GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis", J Allergy Clin Immunol, 144, pp.482~493 (2019)
  52. Suárez-Fariñas M, "RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications", J Allergy Clin Immunol, 135, pp.1218~1227 (2015)
  53. Cavaliere C, "The spectrum of therapeutic activity of mepolizumab", Expert Rev Clin Immunol, 15, pp.959~967 (2019)
  54. Kang EG, "Efficacy and safety of mepolizumab administered subcutaneously for moderate to severe atopic dermatitis", Allergy, 75, pp.950~953 (2020)
  55. Czarnowicki T, "Atopic dermatitis endotypes and implications for targeted therapeutics", J Allergy Clin Immunol, 143, pp.1~11 (2019)
  56. Khattri S, "Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis", Exp Dermatol, 26, pp.28~35 (2017)
  57. "Investigation of Efficacy of Secukinumab in Patients with Moderate to Serve Atopic Dermatitis (Secu_in_AD)" (2018)[URL]
  58. Guttman-Yassky E, "IL-17C : a unique epithelial cytokine with potential for targeting across the spectrum of atopic dermatitis and psoriasis", J Invest Dermatol, 138, pp.1467~1469 (2018)
  59. Guttman-Yassky E, "Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-tosevere atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial", J Am Acad Dermatol, 78, pp.872~881 (2018)

관련 논문AI추천

From Bench to Clinic: the Potential of Therapeutic Targeting of the IL-22 Signaling Pathway in Atopic Dermatitis윤주한, 진미림대한면역학회 · Immune Network2018 · 제18권 제6호Therapeutic New Era for Atopic Dermatitis: Part 2. Small Molecules안지영, 최유성, Simpson Eric Lawrence대한피부과학회 · Annals of Dermatology2021 · 제33권 제2호Th Pathways in Immune-Mediated Skin Disorders: A Guide for Strategic Treatment DecisionsArno Belpaire, Jo Lambert, Marijn Speeckaert, Nanja van Geel, Reinhart Speeckaert대한면역학회 · Immune Network2024 · 제24권 제5호아토피피부염의 표현형과 내재형김민지, 김지현대한 소아알레르기 호흡기학회 · Allergy Asthma & Respiratory Disease2020 · 제8권 제1호Immunopathology and Immunotherapy of Inflammatory Skin Diseases김종훈, 송아름, 이상은대한면역학회 · Immune Network2022 · 제22권 제1호Unraveling the Pathogenesis of Asian Atopic Dermatitis: Key Characteristics and Insights이설희, Ha Nam Gyoung, Jang Yong Hyun대한피부과학회 · Annals of Dermatology2025 · 제37권 제6호

이 간행물의 다른 논문 (16건)

A Novel Mutation p.L461P in KRT5 Causing Localized Epidermolysis Bullosa SimplexJiang Xin, Zhu Yingyu, Sun Huihui, Gu Fengpp. 11-17PTEN Promoter Hypermethylation Is Associated with Breslow Thickness in Acral Melanoma on the Heel, Forefoot, and Hallux정기양, 조미연, 노미령, 김종훈, 박해석pp. 18-25Keratinocytes-Derived Reactive Oxygen Species Play an Active Role to Induce Type 2 Inflammation of the Skin: A Pathogenic Role of Reactive Oxygen Species at the Early Phase of Atopic Dermatitis이지범, 박준형, 최지영, 이승철, 서민송, 윤숙정, 최다인, Piao MeiShanpp. 26-36Exogenous Local Hyperthermia at 41℃ Is Effective to Eliminate Mouse Model of Sporotrichosis, Independent of Neutrophil Extracellular Traps FormationGao Xing-Hua, Li Zheng-Xiu, Lan Jing, Qi Rui-Qun, Wang Ya-Lanpp. 37-45Alitretinoin Compliance in Patients with Chronic Hand Eczema박소희, 김효진, 김종욱, 박인호, 정소영, 홍성민, 조경제, 진우정, 설정은pp. 46-51
원문 보기